Description

Simple

Clinical

Overview

An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.

Pharmacology

Indication

Remoxipride is an atypical antipsychotic once used for the treatment of schizophrenia.

Pharmacodynamic

Remoxipride, a substituted benzamide, is a selective D2 receptor antagonist. It has been shown to be effective in the treatment of schizophrenia. Some antipsychotics block domapinergic receptors as well as cholinergic, noradrenergic and histaminergic receptors. Remoxipride was developed to act speci... Read more

Mechanism of action

Remoxipride acts as an antagonist at the D2 dopamine receptor. It is believed that overactivity of dopamine systems in the mesolimbic pathway may contribute to the "positive symptoms" of schizophrenia (such as delusions and hallucinations), whereas problems with dopamine function in the mesocortical... Read more

Absorption

Rapidly absorbed. Absolute bioavailability is 90%.

Protein binding

89-98%

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

4-7 hours

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

  • Take with or without food. The absorption is unaffected by food.

Interactions

Type in a drug name to check for interaction with Remoxipride
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine
The metabolism of Remoxipride can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.
2,5-Dimethoxy-4-ethylamphetamine
Remoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.
2,5-Dimethoxy-4-ethylthioamphetamine
Remoxipride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylthioamphetamine.
4-Bromo-2,5-dimethoxyamphetamine
The risk or severity of adverse effects can be increased when Remoxipride is combined with 4-Bromo-2,5-dimethoxyamphetamine.
4-Methoxyamphetamine
The risk or severity of adverse effects can be increased when Remoxipride is combined with 4-Methoxyamphetamine.
5-methoxy-N,N-dimethyltryptamine
The risk or severity of adverse effects can be increased when Remoxipride is combined with 5-methoxy-N,N-dimethyltryptamine.
7-Nitroindazole
The risk or severity of adverse effects can be increased when Remoxipride is combined with 7-Nitroindazole.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline
The risk or severity of adverse effects can be increased when Remoxipride is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.
Abatacept
The metabolism of Remoxipride can be increased when combined with Abatacept.
Abiraterone
The metabolism of Remoxipride can be decreased when combined with Abiraterone.
Acebutolol
The metabolism of Remoxipride can be decreased when combined with Acebutolol.
Acepromazine
The risk or severity of adverse effects can be increased when Remoxipride is combined with Acepromazine.
Aceprometazine
The risk or severity of adverse effects can be increased when Remoxipride is combined with Aceprometazine.
Acetaminophen
The metabolism of Remoxipride can be decreased when combined with Acetaminophen.
Acetazolamide
The risk or severity of adverse effects can be increased when Remoxipride is combined with Acetazolamide.
Acetophenazine
The risk or severity of adverse effects can be increased when Remoxipride is combined with Acetophenazine.
Acetylglycinamide chloral hydrate
The risk or severity of adverse effects can be increased when Remoxipride is combined with Acetylglycinamide chloral hydrate.
Aclidinium
Remoxipride may increase the central nervous system depressant (CNS depressant) activities of Aclidinium.
Adalimumab
The metabolism of Remoxipride can be increased when combined with Adalimumab.
Adinazolam
The risk or severity of adverse effects can be increased when Remoxipride is combined with Adinazolam.